Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC
Status:
Unknown status
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and
development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and
tumor cell proliferation related kinase -c-Kit kinase. In the phase Ⅲ study, patients who
failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance
were treated with anlotinib（12mg，po. qd. on day 1to14 of a 21-day cycle） or placebo, the
anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS
were 1.4 months and 6.3 months. Therefore,we envisage using anlotinib plus docetaxel treat
the EGFR wild-type advanced Non-small cell lung cancer patients who were failure in the
treatment of chemotherapy with platinum containing drugs, to further improve the patient's
PFS or OS.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Yong Fang
Collaborators:
Huizhou Municipal Central Hospital Huzhou Central Hospital Ningbo No. 1 Hospital Ningbo No.2 Hospital The First Hospital of Jiaxing Zhejiang Cancer Hospital Zhejiang Provincial People's Hospital Zhejiang Provincial People’s Hospital